Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs ... Development of antidrug antibodies are common with the LA GLP1-RAs (except for dulaglutide), but there is little ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist ... and on par with antibody conjugated NuSH analogs.” As for safety, gastrointestinal adverse events ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists (GLP-1RA ... Massachusetts-based companies focused on bifunctional ...

In the SAPPHIRE trial, Scholar Rock tested apitegromab in patients aged two to 12 who were already being treated with the ...

Surging demand for weight loss drugs Wegovy and Zepbound from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) has fueled concerns ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

Shares of Pfizer PFE rose 2.17% on Oct. 7 after a report from The Wall Street Journal stated that activist investor Starboard ...

Skye said that no neuropsychiatric adverse events were observed in Phase 1 data for its monoclonal antibody nimacimab ... with topline data in Q4 2025. The GLP-1R agonist drug being assessed ...

a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting ...